Swiss biotech company, announced today the successful completion of the first and second phase of clinical trials of a vaccine against malaria. When the advanced testing of a new drug in Africa confirmed its efficacy, its possible spread to 2014. According to a press release by the Swiss firm Mymetics, some time ago, bought the rights to an experimental vaccine PeviPRO from the company-developer Pevion, preliminary clinical studies in Switzerland and the United Kingdom are performed. Final testing of vaccine consists of two antigens malaria parasite, the introduction of which the production of antibodies causes these dangerous intracellular parasites. Currently, according to Managing Director Kristan Mymetics Rocha, in development are more similar products from other antigens. As expected, the final phase of clinical trials in the Swiss vaccine in an African country will take. Upon successful completion of the study Mymetics intends to resell the rights to the drug as a major international pharmaceutical company. Every year, the world will be fixed at 500 million cases of malaria and two million deaths from the disease.
No comments:
Post a Comment